Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
Zobair M. Younossi, Linda Henry
PharmacoEconomics, 2015
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
Related Research
- Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age? 2006
- CHEERS to 30 Years of PharmacoEconomics 2021
- Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations 2011
- Is There a Role for Pharmacoeconomics in Decision Making? 2012
- Erratum to Cost—Effective Prescribing in Elderly People 1992
References
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association 2012
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ 2010
- Health‐related quality of life in patients with non‐alcoholic fatty liver disease 2007
- Depression and anxiety in nonalcoholic steatohepatitis: is there any association? 2011
- Fatigue in non-alcoholic fatty liver disease: is there a role for hypothyroidism. 2009